灵芝与云芝和细胞毒性抗癌药物相互作用系统综述
该系统综述检索九大中英文数据库,纳入213项研究(含77项临床研究),评估灵芝或云芝与细胞毒性化疗药联用的药代或药效相互作用。临床研究多显示联用可改善生存、生活质量、缩小肿瘤、免疫调节并减轻化疗副作用,仅两项药代研究显示PSK与替加氟无显著相互作用,但多数临床研究方法学质量不高。
要点
- 灵芝常与顺铂、5-FU、紫杉醇联用,云芝常与替加氟/尿嘧啶、5-FU、丝裂霉素联用。
- 联用可能改善生存、生活质量、缩小肿瘤、免疫调节并减轻化疗副作用,未报告不良反应。
- 仅两项药代研究显示PSK与替加氟无显著相互作用,仍需高质量药代相互作用研究验证。
核心结论
- 灵芝或云芝与细胞毒性药物联用可能增强疗效并改善不良反应,提高癌症患者生活质量。
- 需更多高质量临床研究及药代相互作用研究验证观察结果与机制。
研究设计与样本
- 系统检索九个主要中英文数据库,纳入临床、动物和体外研究,评估灵芝或云芝与细胞毒性药物联用效果。
- 共识别213项研究,其中77项临床研究报告细胞毒性药物与云芝(n=56)或灵芝(n=21)联用。
- 采用Jadad量表评估临床研究质量,多数临床研究的方法学质量中等。
主要发现
- 临床实践中灵芝最常联用顺铂、5-氟尿嘧啶(5-FU)和紫杉醇,云芝更常联用替加氟/尿嘧啶(UFT)/替加氟、5-FU和丝裂霉素。
- 仅两项临床药代动力学研究显示多糖K(PSK)与替加氟无显著相互作用。
- 药效学方面,联用可改善生存(n=31)、生活质量(n=17)、缩小肿瘤病灶(n=22)、免疫调节(n=38)并减轻化疗相关副作用(n=14),未报告不良反应。
临床怎么用
- 临床可考虑灵芝或云芝与细胞毒性化疗药联用以潜在改善疗效和生活质量,但需关注研究质量限制。
- 联用时应优先参考高质量证据,并警惕药代相互作用,尤其涉及替加氟等药物时现有数据有限。
局限性
- 多数临床研究方法学质量不高(Jadad量表评估为中等质量)。
- 仅两项临床药代动力学研究,药代相互作用证据有限。
- 需更多高质量临床研究及药代相互作用研究验证观察结果与机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lingzhi and Yunzhi are medicinal mushrooms commonly used with cytotoxic chemotherapy in cancer patients in Asian countries. The current systematic review aims to identify potential pharmacokinetic or pharmacodynamic interactions from the existing literature to ensure their effective and safe combination usage in cancer patients. METHODS: A systematic search was conducted on nine major Chinese and English databases, including China Journal Net, Allied and Complementary Medicine Database, and Ovid MEDLINE®, etc., to identify clinical, animal, and in-vitro studies that evaluate the effect of combined use of Lingzhi or Yunzhi with cytotoxic drugs. The Jadad scale was used to assess the quality of clinical studies. RESULTS: This search identified 213 studies, including 77 clinical studies that reported on the combined use of cytotoxic drugs with Yunzhi (n = 56) or Lingzhi (n = 21). Majority of these clinical studies demonstrated modest methodological quality. In clinical practice, the most commonly used cytotoxic drugs with Lingzhi were cisplatin, 5-fluorouracil (5-FU) and paclitaxel, whereas Tegafur/uracil (UFT)/Tegafur, 5-FU, and mitomycin were the ones used more often with Yunzhi. Only two clinical pharmacokinetic studies were available showing no significant interactions between Polysaccharide K (PSK) and Tegafur. From the pharmacodynamic interactions perspective, combination uses of Yunzhi/Lingzhi with cytotoxic drugs in clinical practice could lead to improvement in survival (n = 31) and quality of life (n = 17), reduction in tumor lesions (n = 22), immune modulation (n = 38), and alleviation of chemotherapy-related side effects (n = 14) with no reported adverse effects. CONCLUSION: Our findings suggest that the clinical combination use of Lingzhi or Yunzhi with cytotoxic drugs could enhance the efficacy and ameliorate the adverse effects of cytotoxic drugs, leading to improved quality of life in cancer patients. More high quality clinical studies including pharmacokinetic herb-drug interactions studies are warranted to verify these observations and mechanisms involved. Based on the high quality clinical data, pharmacoepidemiology methods and bioinformatics or data mining could be adopt for further identification of clinical meaningful herb-drug interactions in cancer therapies.
引用
- Lam CS, Cheng LP, Zhou LM, et al. Herb-drug interactions between the medicinal mushrooms Lingzhi and Yunzhi and cytotoxic anticancer drugs: a systematic review. Chin Med. 2020. PMID: 32724333. doi:10.1186/s13020-020-00356-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。